<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751660</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000598586</org_study_id>
    <secondary_id>BCCA-H08-01132</secondary_id>
    <nct_id>NCT00751660</nct_id>
  </id_info>
  <brief_title>Screening Methods in Finding Lung Cancer Early in Current or Former Smokers</brief_title>
  <acronym>Pan Can</acronym>
  <official_title>Early Detection of Lung Cancer - A Pan Canadian Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Screening may help doctors find lung cancer sooner, when it may be easier to&#xD;
      treat.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying screening methods to see how well they find lung&#xD;
      cancer early in current or former smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To develop a new multi-modal screening strategy and integrated methods to detect lung&#xD;
           cancer early in current and former smokers.&#xD;
&#xD;
        -  To evaluate the impact of the screening modalities on the quality of life of these&#xD;
           participants.&#xD;
&#xD;
        -  To develop a decision analytic framework for determining the cost and effectiveness of a&#xD;
           novel lung cancer screening strategy in Canada.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Participants undergo spirometry at baseline. Participants also undergo spiral CT scan at&#xD;
      baseline and then at 1 and 2 years. Participants with semi-solid or solid nodules of 5-10 mm&#xD;
      or ground glass opacity (GGO) 8-10 mm or those with growth of an existing nodule, development&#xD;
      of a solid component in GGO, or a new nodule undergo an additional CT scan at 3 months. Some&#xD;
      participants also undergo autofluorescence and white light bronchoscopy and bronchial&#xD;
      biopsies.&#xD;
&#xD;
      Blood samples are collected at baseline and then annually for 2 years for biomarker studies.&#xD;
      Participants diagnosed with lung cancer undergo additional blood sample collection for&#xD;
      biomarker studies.&#xD;
&#xD;
      Participants complete questionnaires on sociodemographic factors, smoking, occupational&#xD;
      exposure, family history, medical data, quality of life, and anxiety at baseline and then&#xD;
      every 6 months for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lung cancer cases detected early by spiral CT scan and autofluorescence bronchoscopy</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of interval lung cancer cases</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage distribution of lung cancer cases</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of lung nodules and differences in geographic distribution across Canada</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of detection of other incidental significant treatable diseases</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and costs of downstream investigation and treatment related to abnormalities found by the screening procedures, whether the final diagnosis is lung cancer or not</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential physical and psychosocial impact on participants</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2504</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Tobacco Use Disorder</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>screening questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchoscopic and lung imaging studies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Current or former smoker&#xD;
&#xD;
               -  A former smoker is defined as one who has stopped smoking ≥ 1 year but &lt; 15 years&#xD;
                  ago&#xD;
&#xD;
          -  Estimated 1-year lung cancer risk ≥ 1%&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Willing to undergo a spiral chest CT scan&#xD;
&#xD;
          -  No severe heart disease (e.g., unstable angina or chronic congestive heart failure)&#xD;
&#xD;
          -  No acute or chronic respiratory failure&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
          -  No other medical condition that, in the opinion of the investigator, would preclude&#xD;
             the participant's safety during study participation or that would unlikely benefit the&#xD;
             participant from screening due to shortened life expectancy from the co-morbidity&#xD;
&#xD;
          -  No diagnosis of cancer, except for any of the following that were previously treated ≥&#xD;
             5 years ago:&#xD;
&#xD;
               -  Non-melanomatous skin cancer&#xD;
&#xD;
               -  Localized prostate cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Superficial bladder cancer&#xD;
&#xD;
          -  No known reaction to xylocaine, salbutamol, midazolam, or alfentanil&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 years since prior chest CT scan&#xD;
&#xD;
          -  No concurrent anti-coagulant treatment (e.g., warfarin or heparin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary Health Sciences Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hopital Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>tobacco use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

